To develop a diagnostic method with no morbidity or mortality for the detection of acute renal transplant rejection.
Summary Background Data
Rejection constitutes the major impediment to the success of transplantation. Currently available methods, including clinical presentation and biochemical organ function parameters, often fail to detect rejection until late stages of progression. Renal biopsies have associated morbidity and mortality and provide only a limited sample of the organ.
Methods
Thirty-four urine samples were collected from 32 renal transplant patients at various stages posttransplantation. Samples were collected from 17 transplant recipients with acute rejection and 15 patients with no rejection. Samples from patients less than 4 days posttransplant were omitted from data analysis due to the presence of excessive inflammatory response proteins. Rejection status was confirmed by kidney biopsy. Specimens were analyzed in triplicate using SELDI mass spectrometry. The obtained spectra were subjected to bioinformatic analysis using ProPeak as well as CART (Classification and Regression Tree) algorithms to identify rejection biomarker candidates. These candidates were identified by their molecular weight and ranked by their ability to distinguish between nonrejection and rejection based on receiver operating characteristic (ROC) analysis. The candidates with the highest area under the ROC curve (AUC) exhibited the best diagnostic performance.
Results
The best candidate biomarkers demonstrated highly successful diagnostic performance: 6.5 kd (AUC ϭ 0.839, P Ͻ .0001), 6.7 kd (AUC ϭ 0.839, P Ͻ .0001), 6.6 kd (AUC ϭ 0.807, P Ͻ .0001), 7.1 kd (AUC ϭ 0.807, P Ͻ .0001), and 13.4 kd (AUC ϭ 0.804, P Ͻ .0001). A separate analysis using the CART algorithm in the Ciphergen Biomarker Pattern Software correctly classified 91% of the 34 specimens in the training set, giving a sensitivity of 83% and specificity of 100% using two separate biomarker candidates at 10.0 kd and 3.4 kd.
Conclusions
Biomarker candidates exist in urine that have the ability to distinguish between renal transplant patients with no rejection and those with acute rejection. These biomarker candidates are the basis for development of a noninvasive method of diagnosing acute rejection without the morbidity and mortality associated with needle biopsy. The combination of biomarkers into a panel for diagnosis leads to the possibility of enhanced diagnostic performance.
Acute rejection continues to be the major impediment to improved success in renal transplantation. Rejection can be defined as the immunologic interaction between host and allograft in which reactivity by the former leads to a sudden deterioration in physiologic function of the latter. [1] [2] [3] [4] [5] [6] [7] Successful management requires early detection along with adequate treatment. Available diagnostic methods include clinical presentation, biochemical parameters, and tissue biopsies. The first two are not infallible. Serum creatinine, usually the first available indication of allograft dysfunction, is not particularly sensitive or specific. 1 Furthermore, it may not reflect early changes, since renal function may not always correlate with histologic improvement. 8 -10 Biopsy of the renal allograft is regarded as the standard for the diagnosis of rejection and delayed graft function. However, percutaneous renal biopsy is costly and has associated morbidity and mortality. Complications include but are not limited to pain, hematuria, arteriovenous fistulas, perirenal hematomas, injury to adjacent viscera, anuria, allograft thrombosis, sepsis, shock, allograft loss, and patient death. 1,10 -12 Biopsies also allow for sampling errors and subsequent disparities between clinical and microscopic findings. 8, 13, 14 We describe here a bioinformatics tool for the characterization of a urinary proteomic pattern for acute rejection. Several factors led us to choose urine as the substrate for our diagnostic examination: collection is risk-free and noninvasive, there is no discomfort to the patient, and there are no collection restraints. Unlike biopsies, urine allows for sampling of the entire organ and therefore should more accurately reflect its physiologic state and level of function.
MATERIALS AND METHODS

Patient Samples
Thirty-four urine samples were collected from 32 renal transplant patients at various stages posttransplantation. Samples were collected from 17 transplant recipients with acute rejection and 15 patients with no rejection. Two patients had paired samples collected before and during a rejection episode. Samples from patients less than 4 days posttransplant were not accepted for data analysis due to the presence of excessive inflammatory response proteins. All cases of rejection were confirmed by biopsy specimens evaluated by an independent, blinded pathologist. Banff 97 classification criteria were used for diagnosis.
Urine Processing
Specimens were centrifuged for 5 minutes at 1,000g to remove sediment. Supernatants were aliquoted and frozen at Ϫ80°C.
Surface Enhanced Laser Desorption Ionization (SELDI) Mass Spectrometry
Processed urine samples were analyzed in triplicate using SELDI 15 and ProteinChip Arrays, 16, 17 with immobilized metal affinity (IMAC-3) and hydrophobic (H4) surface chemistry. IMAC-3 chips were pretreated with 100 mmol/L CuSO 4 and phosphate-buffered saline (PBS) at pH 7.4. H4 chips were pretreated with 50% acetonitrile. Three microliters of urine were added to each chip spot in duplicate. Chips were incubated at 37°C between applications, allowing samples to dry on the chip surface. Specimens were applied to chips in a random pattern to minimize the effects of spot-to-spot variation. Following sample application, IMAC-3 chips were washed with PBS and H4 chips were washed with 20% acetonitrile to remove nonspecific binding components. CHCA (␣-cyano-4-hydroxycinnamic acid) or SPA (sinapinic acid) matrix solution (composed of energy-absorbing molecules) was then added to each chip spot in duplicate. Protein chips were analyzed on a PBS-II mass reader (Ciphergen Biosystems, Fremont, CA) with SELDI 3.0 software. Data were collected by averaging 110 laser shots, with laser intensities and detector sensitivities optimized for each combination of chip and matrix type.
Data Analysis
Mass spectra generated by SELDI mass spectrometry analysis were examined visually to select and label peaks ( Fig. 1 ) with potential to distinguish between prerejection and rejection patients. In addition, SELDI software was used to identify and label all peaks in the spectrum data by applying a threshold to signal-to-noise values. Labeled peaks were normalized to the creatinine content of each urine specimen, through division of peak intensity by creatinine concentration in g/dL. 18 -20 Outliers were determined statistically and removed from the triplicate data sets based on the results of T n tests. In the T n test, a suspected outlier is compared to the overall mean of the data set by subtracting the result in question from the overall mean and dividing by the standard deviation to obtain a T n value. If the T n value is greater than the critical T value (obtained from a table), then the result in question is deemed to be an outlier and not included in the average.
Both visually and computer-labeled peaks were analyzed with ProPeak software (3Z Informatics, Mt. Pleasant, SC) to statistically identify those peaks with the best ability to distinguish between the patient populations. ProPeak software used UMSA (Unified Maximum Separability Analysis) 21, 22 to identify a direction in n-dimensional space along which two data sets are optimally separated. Bootstrap selection ranked peaks according to the strength and consistency of their ability to discriminate between the sets. Peak intensities were log normalized for ProPeak analysis.
The diagnostic performance of highly ranked peaks from UMSA analysis was evaluated by receiver operator characteristic (ROC) curve analysis (Fig. 2) . The ability of the peaks to distinguish between rejection and nonrejection patients was ranked by the area under the ROC curve (AUC). Peaks with AUCs greater than 0.6 were classified as peaks of interest, the highest ones of which (AUCs Ͼ 0.75) are considered candidate biomarkers. Computer-labeled peaks were also subjected to a separate CART (Classification and Regression Tree) analysis, 23 implemented by Ciphergen Biomarker Patterns Software, to identify patterns of biomarkers that distinguish between patient populations.
RESULTS
Visual and UMSA analyses of spectra from renal transplant patients revealed 45 peaks of interest (AUCs Ͼ 0.600) that showed ability to distinguish between rejection and nonrejection urine samples. From these peaks of interest, 16
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Renal Allograft Rejection peaks (AUCs Ͼ 0.750 and P Ͻ 0.0001-0.0009) showed promise as candidate biomarkers for transplant rejection. Thirteen of these peaks (3.4, 4.1, 6.5, 6.6, 6.7, 7.0, 7.1, 7.3, 7.5, 7.8, 8.0, 10.8, and 13.4 kd) were present in a majority of rejection urine samples but absent from most nonrejection specimens. Three peaks (9.0, 9.7, and 9.8) were downregulated with onset of transplant rejection.
The best candidate biomarkers demonstrated highly successful diagnostic performance: 6.5 kd (AUC ϭ 0.839, P Ͻ .0001), 6.7 kd (AUC ϭ 0.839, P Ͻ .0001), 6.6 kd (AUC ϭ 0.807, P Ͻ .0001), 7.1 kd (AUC ϭ 0.807, P Ͻ .0001), and 13.4 kd (AUC ϭ 0.804, P Ͻ .0001). A separate analysis using the CART algorithm in the Ciphergen Biomarker Pattern Software correctly classified 91% of the 34 specimens in the training set, giving a sensitivity of 83% and specificity of 100% on the same training data set using two separate biomarker candidates at 10.0 kd and 3.4 kd. This result is significant because it demonstrates the potential improvement obtained by combining rejection biomarker candidates into a marker panel. Future studies with a much larger sample set are planned to validate the peaks identified by AUC analysis and the CART biomarker panel algorithm.
DISCUSSION
Despite overall improvements associated with advances in immunosuppression regimens, rejection still occurs and has a deleterious effect on graft survival. The projected half-life of grafts transplanted in recent years was found to be almost double among those with no episodes of clinical acute rejection. 3, 24 Acute rejection has been reported to cause a 20% reduction in the 1-year survival rate and a 4-year diminution in the projected half-life of cadaver allografts. 1, 7 During the first year after transplantation, approximately 35% of recipients will experience an episode of acute rejection. 1, 3 Reports also suggest that rejection is detected in 30% of biopsies done in patients thought to be having stable renal function or to have been successfully treated for rejection. 1, 25, 26 The projected half-life of cadaveric renal transplants for recipients with and without an episode of clinical rejection was 7.0 versus 8.8 years and 8.8 versus 17.9 years in 1988 and 1995, respectively. When data corresponding to patients who died with a functioning graft were censored, there was a 31% increase in projected graft half-life during this period for recipients with an episode of rejection. The corresponding increase among patients with no rejection was 110%. 3 The reduction in the relative hazard of graft failure during the first year after transplantation was 7.1% per year from 1988 to 1996 (P Ͻ .001). When further stratified, this reduction was 0.4% among patients with an episode of acute rejection (P ϭ .57) and 6.3% among those with no episodes of acute rejection (P Ͻ .001). The corresponding reduction in the relative hazard of graft failure per year numbers after censoring for patients who died with a functioning allograft was 2.4% (P ϭ .005) and 10.2% (P Ͻ .001), respectively. 3 Development of a noninvasive marker for renal transplant rejection has the potential to radically change the way in which these transplant patients are managed. The present study involving proteomic analysis of urine samples from transplant patients demonstrates the potential of using biomarkers in urine for early detection of renal transplant rejection. Several biomarker candidates have been identified based on their molecular weight, including several that display a high degree of diagnostic potential based on ROC analysis. By optimizing the sensitivity of the test, proteomic analysis could confirm the presence of rejection in patients with clinical and laboratory findings without the need of a biopsy. Optimization of the specificity can lead to a screening test in which few patients without rejection would be further evaluated for a potential rejection episode.
Large numbers of peaks of interest had molecular weights within several percent of one another. The differences in weight were greater than the mass accuracy of the instrumentation (Ͻ0.3%), preventing close peaks from being combined. Variations in chip surface chemistry and laser excitation (based on instrument settings and matrix type) may have accounted for the disparities. Spot-to-spot variation in the angle of incidence for laser desorption may have contributed additional discrepancies. In addition, posttranslational modifications may contribute to mass variants of the same protein or peptide. These limitations can be addressed by identification of the markers of interest. Future studies are planned for isolation and identification of sample components corresponding to the mass peaks of interest. In addition, combinations of biomarker candidates will be performed using logistical regression or multivariate analysis to determine if a panel of multiple markers results in improved diagnostic performance.
In conclusion, we propose a new method for the diagnosis of acute rejection that is noninvasive and has no associated morbidity or mortality. Mass spectral analysis requires a very small sample, results can be obtained in less than 1 hour, and it is highly cost-effective when compared to other clinical and biochemical modalities such as biopsies. In addition, analyte-specific assays developed from the biomarker candidates would have the potential for development of automated analyses for the clinical laboratory. Furthermore, in comparison to needle biopsy, the individual providing the sample does not have to be physically at the laboratory, since samples can be shipped directly to the laboratory. Renal transplant recipients could have their immunosuppression adjusted according to specific individual needs. Continuous noninvasive allograft monitoring by means of urinary proteomic analysis could allow for immu- Renal Allograft Rejection nosuppression doses to be increased or decreased according to each specific case. In such instances, immunosuppression could be lowered, even gradually weaned off, in recipients who show stable allograft function over time. In those in whom early rejection is detected, immunosuppression could be increased until a satisfactory response is achieved. Adequate response to treatment and resolution of rejection could be rapidly verified, preventing overimmunosuppression and its associated consequences.
Finally, let's touch on cost. You are lucky in having this technology sitting there ready to be used. When I showed this to my lab staff, they said, "Hmmm, exciting. But I can't afford to do that." This is an expensive methodology to set up, but once it is up and going it is relatively inexpensive to run the individual samples. Can you give us some ballpark figures as to how expensive this really is? This is an interesting paper: You have shown us proof of concept. You can identify new individual protein markers for rejection in urine in patients following kidney transplant. As you further characterize these, this is opening the door to a new way to look at rejection episodes.
DR. C. WRIGHT PINSON (Nashville, TN): Transplant clinicians have long sought earlier diagnosis of graft rejection to potentially avoid the long-term sequelae of rejection. A cheap, easy, and noninvasive method allows frequent surveillance that might allow detection at a point in the process earlier than what we now term clinically rejection.
Prior efforts have included amino acid analysis, IL-2 and IL-2R assays of bile in liver transplant patients, simple urinary amylase levels in pancreas transplantation, and T-cell population characterization in blood for all different types of transplants. This report represents an early step again in possibly reaching this potential by yet another method.
My questions echo those of Dr. Henderson. You point out that 25 urine samples were from patients that had acute rejection and 15 were from patients who were presumably without rejection at the time. And this is based on our best gold standard now, which is biopsy. However, as you have pointed out, there are regional sampling errors and, in addition, there are up to 30% of patients who appear to have rejection on random biopsies not associated with clinical rejection. Ergo, the gold standard here is flawed. And I suspect, if anything, your method of analysis may actually be more accurate, not less accurate.
Second, I am curious to know what proteins you think these biomarker candidates might represent, both the ones that appear to be upregulated as well as ones that are downregulated. DR. PETER J. FABRI (Tampa, FL): I have two quick questions. First, did you retest against an independent data set other than your original training set to verify that these in fact were appropriate biomarkers of rejection? And more importantly, have you looked prospectively at any patients to see if you can actually identify rejection before it occurs?
DR. HOSEIN SHOKOUH-AMIRI (Memphis, TN): I would like to echo the question that was asked before. First of all, at what time during the renal allograft dysfunction or how early can you detect the rejection? Another cause of the renal allograft dysfunction is the recurrence of the disease. How does this test identify recurrence of the disease? DR. ERNESTO P. MOLMENTI (Baltimore, MD): I would like to thank the Association for the opportunity to present our work, and the discussants for their kind and thoughtful input. In response to Dr. Henderson's comments, I would like to mention that all rejections were biopsy-proven.
Since the present evaluation was more qualitative than quantitative, we concentrated on the detection of rejection rather than on its severity.
Because of the implications associated with its treatment, rejection became the initial endpoint of our study. However, we are also in the process of evaluating other pathologies. Our ultimate goal is to develop a bedside test for the diagnosis of rejection. Although such test will probably be based on our current mass spectroscopy findings, its final version may not necessarily entail analysis by mass spectrometry.
With respect to costs, we estimate that the current processing of each specimen is approximately $35. I appreciate Dr. Pinson's comments as well.
The advantage of proteomic analysis over other published methods is that it allows us to look at rejection itself. Rather than having to speculate on putative key components of an immunologic cascade, we concentrate on identifying and characterizing biomarkers.
With respect to the accuracy of biopsies, I believe that with time we will transform this test into the new standard for the diagnosis of renal allograft rejection.
As mentioned by Dr. Zibari, we are in the process of evaluating our method in liver and pancreas transplant recipients as well. Three samples obtained in the very early posttransplant period were excluded for practical purposes, since rejection is rarely seen at this stage.
We are currently in the process of detecting biomarkers to characterize delayed graft function. Given that only 3 L are required to perform the analysis, we do not anticipate oliguria to be a major impediment.
In reference to Dr. Fabri's questions, I would like to mention that we are planning a prospective study. I would finally like to thank Dr. Shokouh-Amiri for his comments.
